PORT WASHINGTON, New York – February 25, 2019 Equashield (, a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, announced today a new exclusive partnership with Loginteg SpA and Tecno Farma S.A., who will begin distributing Equashield’s CSTD in Chile and Panama, respectively.

“We are pleased to introduce Equashield’s specialized CSTD solution to Chilean healthcare facilities and are certain that it will contribute to increasing the protection to healthcare workers who are exposed to high risk drugs, either in their preparation or administration.” said Maria Soledad Díaz, Pharmacist, Projects Manager of Loginteg SpA. “Several regulations at the international level have established as mandatory the use of CSTD for administration of these drugs. For instance, USP 800 and the recommendations on the use of CSTD published by the Spanish Society of Hospital Pharmacy both add CSTD requirements.”

Chile is in the process of implementing improved healthcare practice regulations to provide superior protection for healthcare workers. The Chilean Ministry of Health, in its 2016 “Epidemiological surveillance protocol of workers exposed to cytotoxics” recognized the dangers that hazardous drugs pose to healthcare workers. In the protocol, workers directly exposed to hazardous drugs are required to undergo cyclophosphamide urine testing every six months.

Like Chile, Panama has recently started to increase the use of hazardous drug safety products in its health facilities, with several major hospitals and private clinics providing CSTDs for their staff.

“We are providing both technical and scientific support to increase the knowledge of the dangers of exposure to hazardous drugs in Panama,” said Pedro Riley, Tecno Farma S.A. product manager. “Educating healthcare staff on the risks of exposure and the protection provided by CSTDs is an important first step in this market, as we begin to introduce Equashield’s industry leading system to Panama.””

“Healthcare facilities that do not provide protective devices or opt to only use biosafety cabinets or clean room facilities put their health staff at risk of exposure to hazardous vapors and aerosols,” said Adi Shor, VP Sales ROW for Equashield. “Regulation is beginning to move in favor of greater protection for healthcare workers. We believe that through increased market awareness and education, healthcare providers across Latin America will take the necessary steps to protect their staff by implementing CSTDs in addition to other safety measures.”

About Equashield

Equashield is a leading provider of manual and automated solutions for the compounding and administration of hazardous drugs. Equashield’s product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD® Pro, the first ever closed system-enabled Automated Pharmacy Compounding System. Equashield’s CSTD is clinically-proven to protect healthcare professionals from hazardous drug exposure. EQUASHIELD II covers more routes of exposure than alternative systems and has passed the proposed 2015 alcohol vapor containment protocol from NIOSH, confirming that it can contain the harshest vapors & emissions. Studies have shown Equashield’s CSTD as faster to deploy and easier to use than competing systems. Used by hundreds of hospitals and clinics around the world, EQUASHIELD II is CE marked and substantiated by the FDA for preventing microbial ingress for up to seven days.

For more information:

Follow Equashield on LinkedInTwitter and Facebook.

Media Contact:
Finn Partners for Equashield
Nicole Grubner


About Loginteg SpA

Loginteg provides innovative tools to support pharmacists and healthcare professionals’ work. Based on the experience of the international market, the company looks for solutions that benefits the Chilean population, including both healthcare professionals and patients.

For more information: http:/

Follow Loginteg on LinkedIn, Twitter, Facebook and YouTube.